Exegenesis Bio

Exegenesis Bio is a clinical stage global gene therapy company focused on reimagining the development and manufacture of gene therapies. The company's pipeline is built on proprietary capsids, promoters, and unique protein engineering designs, with two programs that have advanced to the clinical stage. The first is a Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China, and the second is a neurovascular AMD (wet AMD) rAAV gene therapy in the USA. They have state-of-the-art cGMP manufacturing facilities, including 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Founded in 2019, Exegenesis Bio has raised over $150 million with its latest Series B investment in February 2021. The investors in this round included K2VC, Kaitai Capital, Legend Capital, Temasek Holdings, BioTrack Capital, LYFE Capital, Hillhouse Investment, Lake Bleu Capital (Hong Kong) Limited, and CPE. It currently employs over 200 scientific and operations staff worldwide. For more information and contacts, visit their website at Exegenesis Bio.